EP0721328A4 - Camptothecin-formulierungen - Google Patents

Camptothecin-formulierungen

Info

Publication number
EP0721328A4
EP0721328A4 EP94929892A EP94929892A EP0721328A4 EP 0721328 A4 EP0721328 A4 EP 0721328A4 EP 94929892 A EP94929892 A EP 94929892A EP 94929892 A EP94929892 A EP 94929892A EP 0721328 A4 EP0721328 A4 EP 0721328A4
Authority
EP
European Patent Office
Prior art keywords
camptothecin formulations
camptothecin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94929892A
Other languages
English (en)
French (fr)
Other versions
EP0721328A1 (de
Inventor
Panayiotis Peri Constantinides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0721328A1 publication Critical patent/EP0721328A1/de
Publication of EP0721328A4 publication Critical patent/EP0721328A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94929892A 1993-09-27 1994-09-27 Camptothecin-formulierungen Withdrawn EP0721328A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12720893A 1993-09-27 1993-09-27
PCT/US1994/010898 WO1995008986A1 (en) 1993-09-27 1994-09-27 Camptothecin formulations
US127208 1998-07-31

Publications (2)

Publication Number Publication Date
EP0721328A1 EP0721328A1 (de) 1996-07-17
EP0721328A4 true EP0721328A4 (de) 1997-09-17

Family

ID=22428860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94929892A Withdrawn EP0721328A4 (de) 1993-09-27 1994-09-27 Camptothecin-formulierungen

Country Status (3)

Country Link
EP (1) EP0721328A4 (de)
JP (1) JPH09504517A (de)
WO (1) WO1995008986A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
BR9812316A (pt) * 1997-09-16 2001-03-20 Nexstar Pharmaceuticals Inc Formulações de camptotecina lipossÈmica
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
ATE238039T1 (de) 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
HK1043310B (zh) * 1999-01-27 2005-10-07 泰立克公司 含有谷胱甘肽类似物的治疗用组合物
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
DE60115044T2 (de) * 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Liposomale antineoplastische arzneimittel und deren verwendungen
WO2002009678A2 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
DE60136490D1 (de) * 2000-11-09 2008-12-18 Neopharm Inc Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
WO2002074246A2 (en) * 2001-03-20 2002-09-26 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
DE10157994A1 (de) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomal verkapselte hydrophobe Wirkstoffe mit hohem Wirkstoffgehalt >50% sowie Verfahren zur Herstellung pharmazeutischer Zubereitungen, die liposomal verkapselte hydrophobe Wirkstoffe umfassen
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
EP1393719A1 (de) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-Carboxylat Formulierungen
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
ES2308208T3 (es) 2003-05-30 2008-12-01 University Of Chicago Metodos y composiciones para predecir la toxicidad del irinotecano.
US20060222694A1 (en) * 2003-06-27 2006-10-05 Oh Choon K Stabilized topotecan liposomal composition and methods
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
ATE450251T1 (de) 2004-05-17 2009-12-15 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CN100356919C (zh) * 2004-05-31 2007-12-26 上海医药工业研究院 羟基喜树碱脂质体及其制备方法
CN1960729B (zh) 2004-06-01 2012-04-11 泰尔茂株式会社 伊立替康制剂
CA2570329C (en) * 2004-06-18 2009-09-01 Terumo Kabushiki Kaisha Liposome preparation containing slightly water-soluble camptothecin
JP4990786B2 (ja) * 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
EP1676568A1 (de) * 2004-12-30 2006-07-05 Merckle Gmbh Phospholipide enthaltende Teilchen sowie deren Herstellung und Verwendung als Arzneimittel
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
JP2015524411A (ja) * 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
KR102310697B1 (ko) 2012-11-20 2021-10-12 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
EP3608308B1 (de) 2013-03-08 2021-07-21 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3169309B1 (de) 2014-07-16 2023-05-10 Novartis AG Verfahren zur verkapselung einer nukleinsäure in einem lipidnanopartikelhost
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
PL439632A1 (pl) * 2021-11-23 2023-05-29 Uniwersytet Warszawski Nośnik lipidowy leku, formulacja farmaceutyczna, ich zastosowania oraz sposób wytwarzania nośnika lipidowego leku, nośnik otrzymany takim sposobem oraz jego zastosowania

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9508986A1 *

Also Published As

Publication number Publication date
WO1995008986A1 (en) 1995-04-06
EP0721328A1 (de) 1996-07-17
JPH09504517A (ja) 1997-05-06

Similar Documents

Publication Publication Date Title
IL111004A0 (en) Oral rapamycin formulations
GB9207832D0 (en) Formulations
ZA945653B (en) Therapeutic compositions
AP9400704A0 (en) Novel formulation
ZA946195B (en) Anthelmintic formulations
GB9410252D0 (en) Galenic formulations
GB9214390D0 (en) Formulations
GB9311030D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9308622D0 (en) Formulations
GB9306144D0 (en) Formulations
GB9202474D0 (en) Formulations
GB9224539D0 (en) Formulations
GB9213271D0 (en) Formulations
GB9205739D0 (en) Formulations
GB9205738D0 (en) Formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9312344D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations
GB9304797D0 (en) Pharmaceutical formulations
GB9304799D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19970731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000401